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The presence of immunoglobulin molecules on the surface of lymphoid cells, particularly on cells derived from bone marrow, is now well established (1) (2) (3) (4) . This evidence includes the demonstration of immunoglobulin molecules on the surface of lymphoid cells by immunofluorescent techniques with antisera to immunoglobulins (1) , by the adherence of immunocompetent cells to bead columns coated with antisera to immunoglobulins (2) , and by isolation of immunoglobulins from the surface of malignant and normal lymphoid cells (3, 4) . Thus far, nonspecific suppression of the antibody response has been achieved by antisera directed against the heavy or light chains of immunoglobulins (5, 6) . Finally, suicidal killing of receptor-bearing cells by heavily labeled antigen (7) is specific for the antigen but yields no information as to the nature and biological function of the antigen-sensitive cell.
Circumstantial evidence now suggests that the combining site of the receptor molecules present on cells specifically reactive to an antigenic determinant is similar to the combining site of the antibody produced in response to the antigen (8) . Our objective was to obtain antibodies directed against the receptor molecules for a single antigenic determinant and to use those antibodies to specifically suppress the response to only that antigen. We used Balb/c myeloma proteins with antibody activity against the hapten phosphorylcholine to prepare anti-idiotypic antibodies in A/He mice. These antiidiotypic antibodies specifically inhibited plaique formation by cells releasing IgM antibody to phosphorylcholine (9) .
Preliminary results (10) also indicated that such anti-idiotypic antibodies specifically suppressed induction of the immune response to phosphorylcholine. Thus, anti-idiotypic antibodies are operationally "anti-receptor" antibodies, and we refer to them as such. In the present paper, we extend these observations and suggest a possible role of such antibodies in regulation of the immune response.
MATERUILS AND METHODS
Animals. 8-to 12-week-old female Balb/c mice from Cumberland Farms were used in all experiments.
Antigens. Strain R36A, rough pneumococci was obtained from the American Type Culture. Pneumococci were killed by exposure to heat at 900 for 60 min and preserved in 0.6% Formalin-0.15 M NaCl. Sheep erythrocytes were obtained from a single sheep maintained at the University of Chicago animal quarters.
Immunization. Mice were injected intravenously with 109 heat-killed pneumococci in 0.2 ml of 0.15 M NaCl or with 0.2 ml of 20% suspension of sheep erythrocytes in 0.15 M NaCl. A drop containing 106 heat-killed pneumococci in minimal essential medium or a drop of 1.25% suspension in sheep erythrocytes in the same medium was added to spleen-cell cultures (107 cells per ml).
Spleen-Cell Cultures. The preparation of spleen-cell cultures has been described (11 technique (13), as modified for use with microscope slides (14) . As target cells for detection of antibodies to phosphorylcholine, sheep erythrocytes were diazotized with phosphorylcholine or coated with penumococcal C-polysaccharide (9) .
Preparation of Antisera. Balb/c mice bearing IgA plasmacell tumors TEPC-15 or MOPC-167 were given to us by Dr. Michael Potter. The myeloma proteins secreted by these tumors bind phosphorylcholine and also precipitate the Cpolysaccharide of pneumococci R36A. An immunoabsorbent column (16) consisting of phosphorylcholine diazotized to sepharose beads was used to purify the myeloma proteins in their monomeric form. Antisera against TEPC 15 and MOPC 167 myeloma proteins were prepared in A/He mice as described by Potter and Lieberman (15) . The antisera were heat-inactivated and absorbed with normal Balb/c serum. Each antiserum reacted only with the myeloma protein used for immunization. (Fig. lb) corresponds remarkably closely to the response in vivo, except that PFC decrease rapidly by day 5 due to deterioration of culture conditions.
The kinetics and magnitude of the responses either in vivo or in vitro are equivalent whether sheep erythrocytes diazotized with phosphorylcholine or coated with pneumococcal C-polysaccharide are used as target cells. Apparently, phosphorylcholine is the major antigenic determinant to which the antibodies against the pneumococcal antigen are directed (9), at least as measured here. For convenience, the antibody elicited by the pneumococci is referred to as antibody directed against phosphorylcholine even though sheep erythrocytes coated with pneumococcal C-polysaccharide were used as target cells in the following experiments. 15 min and incubated in guinea-pig complement for 1 hr. The antiserum against TEPC-15 completely prevented formation of plaques at a dilution of 1:100 and inhibited about 50% of plaques at a dilution of 1:10,000 (Fig. 2) . The antiserum against MOPC 167 failed to inhibit formation of plaques even at low dilutions. Neither antiserum inhibited formation of plaques to sheep erythrocytes.
Presumably, the antiserum to TEPC-15 suppresses plaque formation because it combines with the region of the combining site of antibody to phosphorylcholine. By inference, the antiserum to MOPC-167 is not directed against antibody reactive with phosphorylcholine. The following experiments report the effects of both antisera on induction of the antibody response to phosphorylcholine.
Specific inhibition of induction of the antibody response to phosphorylcholine by antibody to TEPC 15 The effect of antibody to TEPC 15 or MOPC 167 on the response to phosphorylcholine was tested both in vitro and in vivo. For the first set of observations, cultures of normal Balb/c spleen cells were immunized at day 0 with either pneumococci or sheep erythrocytes (see Methods). 0.1 ml of a 1:10 dilution of antiserum to TEPC 15 was added to cultures at the time of immunization or 1, 2, or 3 days later. The same amount of antiserum to MOPC 167 was added to other 15. The following day the animals were immunized intravenously with 109 pneumococci in 0.2 ml of 0.15 M NaCl or with 0.2 ml of a 20% sheep-erythrocyte suspension in 0.15 M NaCl; the spleens were individually assayed for PFC against either untreated or sheep erythrocytes coated with pneumococcal C-polysaccharide at day 4 after immunization. The number of plaques is given per spleen, and it represents the average of four spleens (five slides per spleen).
cultures at the time of immunization. The antisera were left in the culture dishes until they were assayed at day 4; the results (Table 1) show that antiserum to TEPC 15 completely suppressed the response when added at the time of immunization. Suppression resulted from inhibition of induction rather than from inhibition of plaque-formation, since antiserum added 1 or more days after immunization had no suppressive effect. Antiserum to MOPC 167 had no inhibitory effect on the antibody response to phosphorylcholine; neither antisera suppressed the response to sheep erythrocytes.
Antiserum to TEPC 15 was similarly effective in suppressing the response to phosphorylcholine in vivo. Three groups of eight Balb/c mice each were injected intraperitoneally with 0.3 ml of antiserum to TEPC 15, to MOPC 167, or with normal A/He serum. The following day, four of the mice in each group were injected intravenously with pneumococci and the other four with sheep erythrocytes (Table  2 ). The PFC responses were measured 4 coated with pneumococcal C-polysaccharide). Furthermore, antibodies to TEPC 15 also seem to be specifically directed against the binding-site region of receptor molecules onantigensensitive cells, since they prevent induction of the antibody response only to phosphorylcholine. Thus, the cell receptor for phosphorylcholine shares similar antigen-binding structures with antibodies to phosphorylcholine and with TEPC-15 myeloma. Inhibition of induction of the response to phosphorylcholine is probably due to binding of the antibodies to TEPC 15 to the receptor molecules preventing stimulation by the pneumococcal antigen. Thus, we believe that these observations permit us to conclude that the antiserum to TEPC 15 contains "anti-receptor" antibodies.
Cell receptors are thought to be of IgM or of IgG classes (3, 5) , possibly sharing the K class of light chain (6) . Thus, the combining-site region of the receptor for phosphorylcholine, regardless of its class of heavy and light chains, must be similar to the combining site of the IgM antibody synthesized in the primary response to phosphorylcholine and of the TEPC-15 IgA myeloma. The general implication is that antibodies and antigen receptors belonging to different immunoglobulin classes but having specificity for the same antigen may share similar binding-site regions encoded by identical variable genes (17) .
The complete inhibition of the antibody response to phosphorylcholine by antibodies to TEPC 15 
